Global Biopharmaceuticals Market 2023-2029
Biopharmaceuticals, also known as biologics, are a class of drugs that are produced using living cells or organisms. They are typically large, complex molecules, such as proteins, nucleic acids, or antibodies, that are used to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. Biopharmaceuticals are produced using biotechnology techniques, such as genetic engineering, fermentation, and cell culture. They are designed to target specific molecules or cells in the body, and may be more effective and have fewer side effects than traditional small molecule drugs. According to the latest estimates, the global biopharmaceuticals market is set to achieve an incremental growth of USD 283.5 million, accelerating at a CAGR of almost 7.99% during the forecast period 2023-2029.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global biopharmaceuticals market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product type, application, and region. The global market for biopharmaceuticals can be segmented by product type: monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzymes, cell and gene therapies, synthetic immunomodulators, others. According to the research, the monoclonal antibodies segment had the largest share in the global biopharmaceuticals market. Biopharmaceuticals market is further segmented by application: oncology, autoimmune disorders, inflammatory and infectious diseases, metabolic disorders, other therapeutic, neurological diseases, cardiovascular diseases, hormonal disorders. In 2022, the inflammatory and infectious diseases segment made up the largest share of revenue generated by the biopharmaceuticals market. Based on region, the biopharmaceuticals market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. Among these, North America was accounted for the highest revenue generator in 2022.
The monoclonal antibodies market is further segmented into anti-cancer monoclonal antibodies, anti-inflammatory monoclonal antibodies, others. The latest analysis indicates that the anti-cancer monoclonal antibodies segment occupied the largest share of this market in 2022 and is expected to draw the highest demand in coming years. Furthermore, the recombinant hormones market has been categorized into recombinant human growth hormones, recombinant insulin, others. Globally, the recombinant insulin segment made up the largest share of the biopharmaceuticals market. The vaccines market is further divided into recombinant vaccines, convectional vaccines. The recombinant vaccines segment was the largest contributor to the global biopharmaceuticals market in 2022. The recombinant growth factors market is further segmented into erythropoietin, granulocyte colony stimulating factor. The latest analysis indicates that the erythropoietin segment occupied the largest share of this market in 2022 and is expected to draw the highest demand in coming years. Furthermore, the recombinant proteins market has been categorized into serum albumin, amyloid protein, defensin, transferrin. Globally, the transferrin segment made up the largest share of the biopharmaceuticals market.
Market Segmentation
By product type: monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzymes, cell and gene therapies, synthetic immunomodulators, others
By application: oncology, autoimmune disorders, inflammatory and infectious diseases, metabolic disorders, other therapeutic, neurological diseases, cardiovascular diseases, hormonal disorders
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The report also provides analysis of the key companies of the industry and their detailed company profiles including AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, Bristol Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Novo Nordisk AS, GSK plc, F. Hoffmann-la Roche Ltd., Sanofi SA, Astrazeneca plc, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Scope of the Report
To analyze and forecast the market size of the global biopharmaceuticals market.
To classify and forecast the global biopharmaceuticals market based on product type, application, region.
To identify drivers and challenges for the global biopharmaceuticals market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global biopharmaceuticals market.
To identify and analyze the profile of leading players operating in the global biopharmaceuticals market.
Why Choose This Report
Gain a reliable outlook of the global biopharmaceuticals market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global biopharmaceuticals market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product type, application, and region. The global market for biopharmaceuticals can be segmented by product type: monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzymes, cell and gene therapies, synthetic immunomodulators, others. According to the research, the monoclonal antibodies segment had the largest share in the global biopharmaceuticals market. Biopharmaceuticals market is further segmented by application: oncology, autoimmune disorders, inflammatory and infectious diseases, metabolic disorders, other therapeutic, neurological diseases, cardiovascular diseases, hormonal disorders. In 2022, the inflammatory and infectious diseases segment made up the largest share of revenue generated by the biopharmaceuticals market. Based on region, the biopharmaceuticals market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. Among these, North America was accounted for the highest revenue generator in 2022.
The monoclonal antibodies market is further segmented into anti-cancer monoclonal antibodies, anti-inflammatory monoclonal antibodies, others. The latest analysis indicates that the anti-cancer monoclonal antibodies segment occupied the largest share of this market in 2022 and is expected to draw the highest demand in coming years. Furthermore, the recombinant hormones market has been categorized into recombinant human growth hormones, recombinant insulin, others. Globally, the recombinant insulin segment made up the largest share of the biopharmaceuticals market. The vaccines market is further divided into recombinant vaccines, convectional vaccines. The recombinant vaccines segment was the largest contributor to the global biopharmaceuticals market in 2022. The recombinant growth factors market is further segmented into erythropoietin, granulocyte colony stimulating factor. The latest analysis indicates that the erythropoietin segment occupied the largest share of this market in 2022 and is expected to draw the highest demand in coming years. Furthermore, the recombinant proteins market has been categorized into serum albumin, amyloid protein, defensin, transferrin. Globally, the transferrin segment made up the largest share of the biopharmaceuticals market.
Market Segmentation
By product type: monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzymes, cell and gene therapies, synthetic immunomodulators, others
By application: oncology, autoimmune disorders, inflammatory and infectious diseases, metabolic disorders, other therapeutic, neurological diseases, cardiovascular diseases, hormonal disorders
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The report also provides analysis of the key companies of the industry and their detailed company profiles including AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, Bristol Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Novo Nordisk AS, GSK plc, F. Hoffmann-la Roche Ltd., Sanofi SA, Astrazeneca plc, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Scope of the Report
To analyze and forecast the market size of the global biopharmaceuticals market.
To classify and forecast the global biopharmaceuticals market based on product type, application, region.
To identify drivers and challenges for the global biopharmaceuticals market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global biopharmaceuticals market.
To identify and analyze the profile of leading players operating in the global biopharmaceuticals market.
Why Choose This Report
Gain a reliable outlook of the global biopharmaceuticals market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
PART 1. INTRODUCTION
Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
Introduction
Drivers
Restraints
PART 5. MARKET BREAKDOWN BY PRODUCT TYPE
Monoclonal antibodies
Recombinant growth factors
Purified proteins
Recombinant proteins
Recombinant hormones
Vaccines
Recombinant enzymes
Cell and gene therapies
Synthetic immunomodulators
Others
PART 6. MARKET BREAKDOWN BY APPLICATION
Oncology
Autoimmune disorders
Inflammatory and infectious diseases
Metabolic disorders
Other therapeutic
Neurological diseases
Cardiovascular diseases
Hormonal disorders
PART 7. MARKET BREAKDOWN BY REGION
North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America
PART 8. KEY COMPANIES
AbbVie Inc.
Amgen Inc.
Pfizer Inc.
Novartis AG
Bristol Myers Squibb Company
Eli Lilly and Company
Johnson & Johnson
Novo Nordisk AS
GSK plc
F. Hoffmann-la Roche Ltd.
Sanofi SA
Astrazeneca plc
DISCLAIMER
Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
Introduction
Drivers
Restraints
PART 5. MARKET BREAKDOWN BY PRODUCT TYPE
Monoclonal antibodies
Recombinant growth factors
Purified proteins
Recombinant proteins
Recombinant hormones
Vaccines
Recombinant enzymes
Cell and gene therapies
Synthetic immunomodulators
Others
PART 6. MARKET BREAKDOWN BY APPLICATION
Oncology
Autoimmune disorders
Inflammatory and infectious diseases
Metabolic disorders
Other therapeutic
Neurological diseases
Cardiovascular diseases
Hormonal disorders
PART 7. MARKET BREAKDOWN BY REGION
North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America
PART 8. KEY COMPANIES
AbbVie Inc.
Amgen Inc.
Pfizer Inc.
Novartis AG
Bristol Myers Squibb Company
Eli Lilly and Company
Johnson & Johnson
Novo Nordisk AS
GSK plc
F. Hoffmann-la Roche Ltd.
Sanofi SA
Astrazeneca plc
DISCLAIMER
